Cargando…

Mechanism of intrinsic resistance of lung squamous cell carcinoma to epithelial growth factor receptor-tyrosine kinase inhibitors revealed by high-throughput RNA interference screening

Although targeted therapy has achieved a great breakthrough in the treatment of lung adenocarcinoma, there are still no effective targeted drugs for lung squamous cell carcinoma (SqCC). In addition, as immunotherapy can only prolong the overall survival (OS) of lung SqCC by ≤5 months, chemotherapy a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ju, Lixia, Dong, Zhiyi, Yang, Juan, Li, Minghua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590427/ https://www.ncbi.nlm.nih.gov/pubmed/33133263 http://dx.doi.org/10.3892/ol.2020.12218

Ejemplares similares

An in silico high-throughput screen identifies potential selective inhibitors for the non-receptor tyrosine kinase Pyk2
por: Meirson, Tomer, et al.
Publicado: (2017)

Cellular Assays for High-Throughput Screening for Modulators of Trk Receptor Tyrosine Kinases
por: Wang, Jun, et al.
Publicado: (2008)

Tumor exome sequencing and copy number alterations reveal potential predictors of intrinsic resistance to multi-targeted tyrosine kinase inhibitors
por: Gillis, Nancy K., et al.
Publicado: (2017)

High-throughput kinase inhibitor screening reveals roles for Aurora and Nuak kinases in neurite initiation and dendritic branching
por: Blazejewski, Sara M., et al.
Publicado: (2021)

Icotinib derivatives as tyrosine kinase inhibitors with anti-esophageal squamous carcinoma activity
por: Chen, Xiaojie, et al.
Publicado: (2022)

A High-Throughput Screen Reveals New Small-Molecule Activators and Inhibitors of Pantothenate Kinases
por: Sharma, Lalit Kumar, et al.
Publicado: (2015)

Metastatic Squamous Cell Carcinoma from Lung Adenocarcinoma after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy
por: Park, Hyung Kyu, et al.
Publicado: (2017)

Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma
por: Busch, Jonas, et al.
Publicado: (2011)

A dynamic N(6)-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors
por: Yan, Fei, et al.
Publicado: (2018)

De novo MET amplification promotes intrinsic resistance to first-generation EGFR tyrosine kinase inhibitors
por: Li, Jing-Wen, et al.
Publicado: (2019)

Tyrosine Kinase Inhibitors and Interferon
por: Dimou, Maria, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitors for the Elderly
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2016)

Tyrosine Kinase Inhibitors and Pregnancy
por: Abruzzese, Elisabetta, et al.
Publicado: (2014)

Nanomedicine of tyrosine kinase inhibitors
por: Smidova, Veronika, et al.
Publicado: (2021)

High-Throughput Screening to Predict Chemical-Assay Interference
por: Borrel, Alexandre, et al.
Publicado: (2020)

Epidermal growth factor receptor tyrosine kinase inhibitors
por: Ranson, M
Publicado: (2004)

β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia
por: Eiring, Anna M., et al.
Publicado: (2015)

A184 REPURPOSING DRUGS FOR SPLEEN TYROSINE KINASE (SYK) PEDIATRIC PATIENTS USING HIGH-THROUGHPUT SCREENING
por: Chau, S, et al.
Publicado: (2022)

Identification of Compounds That Interfere with High‐Throughput Screening Assay Technologies
por: David, Laurianne, et al.
Publicado: (2019)

Latest progress in tyrosine kinase inhibitors
por: Pospelova, Tatiana V., et al.
Publicado: (2014)

Tyrosine kinase inhibitors in sarcoma treatment
por: Kyriazoglou, Anastasios, et al.
Publicado: (2022)

Development of a Robust High-Throughput Screening Platform for Inhibitors of the Striatal-Enriched Tyrosine Phosphatase (STEP)
por: Lambert, Lester J, et al.
Publicado: (2021)

Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
por: Wang, Jun, et al.
Publicado: (2016)

Regulation of branching dynamics by axon-intrinsic asymmetries in Tyrosine Kinase Receptor signaling
por: Zschätzsch, Marlen, et al.
Publicado: (2014)

The Inherent Coupling of Intrinsically Disordered Regions in the Multidomain Receptor Tyrosine Kinase KIT
por: Ledoux, Julie, et al.
Publicado: (2022)

In Vitro High Throughput Screening, What Next? Lessons from the Screening for Aurora Kinase Inhibitors
por: Hoang, Thi-My-Nhung, et al.
Publicado: (2014)

Motogenic and morphogenic activity of epithelial receptor tyrosine kinases
Publicado: (1996)

Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer
por: Labots, Mariette, et al.
Publicado: (2016)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

A Case of Squamous Cell Carcinoma of Unknown Primary that Responded to the Multi-Tyrosine Kinase Inhibitor Lenvatinib
por: Kimura-Tsuchiya, Reiko, et al.
Publicado: (2018)

Clinical value of monoclonal antibodies and tyrosine kinase inhibitors in the treatment of head and neck squamous cell carcinoma
por: Blaszczak, Wiktoria, et al.
Publicado: (2017)

Molecular docking of 1H-pyrazole derivatives to receptor tyrosine kinase and protein kinase for screening potential inhibitors
por: Chandra,, et al.
Publicado: (2014)

The Interference between SARS-CoV-2 and Tyrosine Kinase Receptor Signaling in Cancer
por: Purcaru, Oana-Stefana, et al.
Publicado: (2021)

Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab
por: Chen, Gang, et al.
Publicado: (2012)

Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis
por: Gomez-Puerta, Jose A., et al.
Publicado: (2013)

Reversing multidrug resistance by tyrosine kinase inhibitors
por: He, Miao, et al.
Publicado: (2012)

Fasting plus tyrosine kinase inhibitors in cancer
por: Caffa, Irene, et al.
Publicado: (2015)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
por: Huang, Lihua, et al.
Publicado: (2015)

Second-generation inhibitors of Bruton tyrosine kinase
por: Wu, Jingjing, et al.
Publicado: (2016)

Targeting tumour microenvironment by tyrosine kinase inhibitor
por: Tan, Hor-Yue, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_kmijsaomb1ahr16ujtu0pb5gdq